Teijin Pharma Limited.

Industry

  • Pharmaceuticals
    • Vaccines
  • Medical Devices
    • Rehabilitation Equipment and Devices
  • Digital Health
    • Disease Management

Other Names/Subsidiaries

  • MedTech Heart
  • Teijin Corporation
  • TEIJIN NAKASHIMA MEDICAL
  • Japan Tissue Engineering (J-TEC)
See more in Biomedtracker

Latest on Teijin Pharma Limited.

Scrip

Chiesi Takes Long View To Build Japan Rare Disease Presence

 
• By Lisa Takagi

Chiesi Farmaceutici S.p.A. is actively expanding its rare disease business in Japan through a subsidiary established there in 2022 and as part of the family-owned Italian firm's global push into this

Scrip

Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA

 
• By Joseph Haas, Dexter Jie Yan, Vibha Ravi, Lisa Takagi, and Anju Ghangurde

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. MiNA Will Provide RNAa Candidates

Pink Sheet

Japan Drug Price Revision: Cuts, Increases Aim To Balance National Healthcare Costs

 
• By Lisa Takagi

In a long-running effort to balance growth in national healthcare costs in a rapidly ageing society and promote stability in a flat pharmaceutical market, Japan has announced details of its annual dru

Scrip

Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate

 
• By Dexter Jie Yan, Lisa Takagi, Jung Won Shin, and Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. AnnJi Licenses Muscular Atrophy Ca